A Phase Ib, Multi-center, Open-Lable, Dose-Escalation and Dose-Expansion Study of Efficacy and Safety of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors
Latest Information Update: 08 Feb 2024
At a glance
- Drugs Ficonalkib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shouyao Holdings
- 01 Feb 2024 Planned End Date changed from 30 Dec 2025 to 30 May 2026.
- 01 Feb 2024 Planned primary completion date changed from 30 Jun 2025 to 30 Dec 2025.
- 01 Feb 2024 Planned initiation date changed from 30 Oct 2023 to 30 May 2024.